Meta Health (SGX:5DX) has signed a non-binding term sheet to acquire up to 30% of Aios Bio Sciences, a medical device company, according to a Wednesday filing on the Singapore Exchange.
The deal may also involve a larger stake. Payment could be made through the issuance of new shares in Meta Health, subject to due diligence and further negotiations.
The acquisition aims to diversify Meta Health's business into medical consumables and point-of-care diagnostics. The transaction is contingent on due diligence, board approval, and a 60-day exclusivity period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.